Receptor Occupancy of ITI-007 Using Positron Emission Tomography (PET) in Patients With Stable Schizophrenia

Intra-Cellular Therapies, Inc.14 enrolled

Overview

The purpose of this study is to determine the relationship between ITI-007 dose, plasma levels and brain receptor occupancy in patients with stable schizophrenia.

Study Type

INTERVENTIONAL

Allocation

Purpose

BASIC_SCIENCE

Masking

NONE

Enrollment

Conditions

Schizophrenia

Interventions

ITI-007DRUG

Eligibility

Sex: ALLMin age: 18 YearsMax age: 60 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Patients with schizophrenia who are drug-free with regard to their antipsychotic medication * In clinical remission and free from acute exacerbation of their psychosis * In good health Exclusion Criteria: * Clinically significant medical conditions considered inappropriate for trial participation

Locations (1)

Johns Hopkins Medical Institutions

Baltimore, Maryland, United States

Outcomes

Primary Outcomes

Brain Receptor Occupancy as Measured by Positron Emission Tomography

Time frame: Up to 14 days

Secondary Outcomes

Safety and Tolerability as Measured by Number of Participants with Adverse Events

Time frame: Up to 14 days

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.